NL-OMON43494已完成不适用
89Zr-AMG211 PET imaging in patients with relapsed/refractory gastrointestinal adenocarcinoma before and during treatment with AMG 211. - 89Zr-AMG211 PET imaging study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* Subject will be or is also participating in the ongoing phase 1 study 20130354 in which AMG 211 is administered via cIV. 89Zr-AMG211 PET imaging will be performed before and/or during treatment with AMG 211 cIV.
- •* Subject has provided informed consent to imaging study prior to initiation of any study-specific activities/procedures
- •* Male or Female * 18 years of age at the time of informed consent
- •* Pathologically documented, diagnosed GI adenocarcinoma (including but not limited to esophageal, gastric, small intestine, colorectal, or pancreatic cancers) that has failed standard treatments or for which standard curative or palliative measures do not exist or are no longer effective
- •* At least 1 measurable tumor lesion per modified irRC
- •o In case we do not find any uptake in metastatic liver lesions in the first set of patients on the 89Zr-AMG211 PET scan, than subsequent patients need to have at least 1 measurable tumor lesion outside the liver
- •* Archival tumor tissue available or is willing to undergo biopsy of a tumor lesion before the start of treatment
- •* Adequate hematological, renal, and liver function as follows:
- •o Absolute neutrophil count (ANC) > 1500/mm3 (1.5 × 109/L)
- •o Platelet count > 100,000 mm3 (100 × 109/L)
- •o White blood cell (WBC) count > 3 × 109/L
- •o Hemoglobin > 9.0 g/dL
- •o AST and ALT < 3.0 × the upper limit of normal (ULN)
- •o Alkaline phosphatase (ALP) * 2.5 × ULN
- •o Total bilirubin (TBL) < 1.5 × ULN (unless subject has suspected Gilbert*s syndrome or extrahepatic cause by increased indirect bilirubin fraction)
- •o Creatinine clearance > 50 mL/min calculated by Cockroft-Gault
- •o Lipase/amylase < 1.5 x ULN
- •o Prothrombin time, partial thromboplastin time, and international normalized ratio (INR) * 1.5 × ULN
- •* Life expectancy * 3 months, in the opinion of the investigator
- •* Karnofsky Performance Status * 70%
- •* Body weight * 45 kg
排除标准
- •* History of allergy or reaction to any component of the AMG 211 formulation
- •* Malignancy other than GI adenocarcinoma requiring current therapy
- •* Evidence of uncontrolled systemic disease (other than GI adenocarcinoma)
- •* Active infection or prior use of IV antibiotics for treatment of infection within 2 weeks prior to starting therapy with AMG 211
- •* Corrected QT interval (QTc) * 500 milliseconds at screening
- •* Hepatitis B and/or C based on the following results:
- •o Positive Hepatitis B Surface Antigen (HepBsAg) (indicative of chronic Hepatitis B or recent acute Hepatitis B)
- •o Negative HepBsAg and positive Hepatitis B core antibody: Hepatitis B virus DNA by polymerase chain reaction (PCR) is necessary. Detectable Hepatitis B virus DNA suggests occult Hepatitis B.
- •o Positive Hepatitis C virus antibody (HepCAb) Hepatitis C virus RNA by PCR is necessary. Detectable Hepatitis C virus RNA suggests chronic Hepatitis C
- •* Positive results for human immunodeficiency virus (HIV)
- •* Major surgery within 28 days of study day 1
- •* Prophylactic anti-infection vaccination within 1 month prior to starting therapy with
- •AMG 211. Therapeutic vaccination for cancer or infection within 3 months prior to starting therapy with AMG 211.
- •* Currently receiving treatment in another investigational device or drug study, or less than 28 days since ending treatment in another investigational device or drug study. Other investigational procedures while participating in this study are excluded.
- •o Exception to this criterion is the participation in Study 20130354 and all procedures related to this study.
- •* Treatment with any chemotherapy, radiotherapy, immunotherapy, biologic, or hormonal therapy for cancer within 14 days prior to study entry or not recovered from treatment
- •* Unresolved toxicities from prior anti-tumor therapy, defined as not having resolved to Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 grade 1 or to levels dictated in the eligibility criteria with the exception of alopecia or toxicities from anti-tumor therapy that are considered irreversible (defined as having been present and stable for > 6 months), may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and the sponsor
- •* Recent history of cardiac disease, including myocardial infarction, unstable angina pectoris, or uncontrolled arrhythmia within 6 months; or evidence of severe congestive heart failure with New York Heart Association severity classification > Class I within 12 weeks prior to screening
- •* History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above), that in the opinion of the investigator or sponsor would pose a risk to subject*s safety or interfere with the study evaluation, procedures, or completion
- •* Clinical history of significant central nervous system (CNS) pathology (including but not limited to: history of brain metastasis, multiple occurrences of confusion, dementia, previous CNS infarctions, migraine headaches [within 6 months prior to starting therapy with AMG 211], seizure disorder, or major brain surgery)
- •* History of chronic autoimmune disease, e.g., rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, or multiple sclerosis (with the exception of stable type 1 diabetes)
- •* Males or Females o
研究者
相似试验
进行中（未招募）
1 期
89Zr-AMG211 PET imaging in patients with relapsed/refractory gastrointestinal adenocarcinoma before and during treatment with AMG 211Relapsed/refractory gastrointestinal adenocarcinomaEUCTR2015-004370-14-NLniversity Medical Center Groningen35
进行中（未招募）
不适用
89Zr-RO5323441 PET scan in patients with recurrent high grade brain tumor treated with bevacizumabEUCTR2011-004974-27-NLniversity Medical Center Groningen
撤回
2 期
89Zr-RO5323441 PET imaging in patients with recurrent glioblastoma treated with bevacizumabrecurrent glioblastoma multiforme10029211brain tumorNL-OMON37750niversitair Medisch Centrum Groningen7
已完成
1 期
89Zr-AMG211 PET Imaging StudyAdvanced Gastrointestinal CancerNCT02760199University Medical Center Groningen9
已完成
不适用
89Zr-pembrolizumab-PET imaging in patients with locally advanced or metastatic melanoma or non-small cell lung cancerMelanoma and non-small cell lung cancer1004090010029107NL-OMON43013niversitair Medisch Centrum Groningen21